Investor Relations

Company Overview

We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer.

We are advancing programs in women’s health, including endometriosis-associated pain and egg maturation in assisted reproduction, including in vitro fertilization (IVF), and the prevention of pregnancy.

Over time, we intend to expand our development pipeline to include potential treatments for women's health.

FDA Approved Drugs: ORGOVYX (relugolix 120 mg), MYFEMBREE (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg)

Data Provided by Refinitiv. Minimum 15 minutes delayed. Market cap from previous market close.

Press Releases
June 17, 2022
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
June 16, 2022
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
June 3, 2022
Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Events

SEC Filings

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.INS - XBRL INSTANCE DOCUMENT

Quarterly report which provides a continuing view of a company's financial position

10-Q View HTML EX-101.INS - XBRL INSTANCE DOCUMENT